Schizophrenia Therapeutic Market Size Share Trends Insights Forecast 2026

1. SCHIZOPHRENIA THERAPEUTIC MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Schizophrenia Therapeutic Market - Overview Schizophrenia Therapeutic Market, by Treatment (First Generation Antipsychotic Drugs and Second Generation Antipsychotic Drugs), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026 Schizophrenia is a mental disorder where the patient suffers from inability to understand the reality, decreased ability of thinking, abnormal behavior, and strange speech. Furthermore, the patient suffers from reduced emotional expression, anxiety, depression or less social engagement. According to the Brain & Behavior Research Foundation, schizophrenia generally occurs between the ages of 16-30. Although the main cause of schizophrenia is unknown, possible reasons are genetic, environmental factors or poor nutrition during pregnancy. Treatment for schizophrenia include, psychological therapies, behavioral therapies, and antipsychotic drugs. Electroconvulsive therapies also aid in the treatment of schizophrenia. In severe cases, hospitalization is necessary for a short period of time. Global Schizophrenia Therapeutic Market Drivers The global schizophrenia therapeutic market size is expected to expand, owing to increasing prevalence of schizophrenia. In 2018, World Health Organization (WHO) reported that over 23 million patientswere affected by schizophrenia worldwide. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing- insight/schizophrenia-therapeutic-market-2468 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Global SchizophreniaTherapeutic Restraints The common negligence and stigma regarding schizophrenia is one of the major restraining factors for hampering the schizophrenia therapeutic market growth. For instance, in 2018, the Schizophrenia and Related Disorders Alliance of America (SARDAA) reported that around 50% of people diagnosed with schizophrenia do not receive treatment, owing to negligence for mental health. Moreover, the side effects caused by antipsychotics such as weight gain, dizziness, restlessness, nausea, blurred vision, low blood pressure, seizures, and constipation can also be negative growth rendering factor for the global schizophrenia therapeutic market revenue. For instance, according to National Centre for Biotechnology Information (NCBI) 2017 findings, obesity is affecting 15%-72% patients, 12% of patients are suffering from diabetes, and the prevalence of constipation is 39% in schizophrenic patients. Consumption of antipsychotics may also lead to sudden cardiac death and ventricular arrhythmia. Global Schizophrenia Therapeutic Market Regional Analysis North America holds dominant position in the schizophrenia therapeutic market, owing to increasing incidences of schizophrenia and high investment in schizophrenia therapy in the region. According to SARDAA, around 3.2 to 3.5 million people in the U.S. were suffering from schizophrenia in 2013. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2468 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION According to the same source, around US$ 32 to US$ 65 billion are annually spent on treatment and other economic costs of schizophrenia in the U.S. Asia Pacific is fastest growing region in schizophrenia therapeutic market due to high prevalence of schizophrenia in economies such as China and India. According to NCBI 2014 data, prevalence of schizophrenia in China was 4.62 per 1000 people. Schizophrenia therapeutic market size is also expected to boost due to launch of new medicines in China. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson launched INVEGA TRINZA in 2018 for the treatment of schizophrenia in China. INVEGA TRINZA is a three-month long-acting atypical antipsychotic drug for insomnia. Global Schizophrenia Therapeutic Market Key Players Key players operating in the global schizophrenia therapeutic market include, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Pfizer, Sandoz Canada Inc., Intas Pharmaceuticals, Novartis AG, Otsuka Pharmaceuticals, Alkermes, Allergan (Forest Labs), and Sumitomo Dainippon Pharma. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2468 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved